Zanubrutinib was granted FDA-accelerated approval based on the results of Phase I and II trials. The investigator-assessed overall response rate was 83.7%, of which 78% of patients achieved complete response. The median duration of response was 19.5 months, and the median progression-free ...
Zanubrutinib is also approved by the FDA for use in WM [35]. In 2020, a thorough review describing research on zanubrutinib to treat WM was published [36]. There have been many advances in WM treatment since then. Another review published in 2022 focused on updated safety and ...